Gutte Shreyas, Gurjar Mohan, Sanjeev Om Prakash, Bhadauria Dharmendra, Kapoor Aditya, Mishra Prabhaker, Azim Afzal, Poddar Banani
Department of Critical Care Medicine, Sanjay Gandhi Post Graduate Institute of Medical Sciences (SGPGIMS), Raebareli Road, Lucknow, India.
Department of Emergency Medicine, Sanjay Gandhi Post Graduate Institute of Medical Sciences (SGPGIMS), Raebareli Road, Lucknow, India.
Indian J Community Med. 2023 May-Jun;48(3):497-500. doi: 10.4103/ijcm.ijcm_663_22. Epub 2023 May 30.
The aim of this study was to access the incidence of prolonged QTc interval and changes, if any, among Indian healthcare workers (HCWs) taking hydroxychloroquine (HCQ) prophylaxis while managing coronavirus disease 2019 (COVID-19) cases.
At the beginning of the COVID-19 pandemic, as per the Indian Council of Medical Research (ICMR) policy, HCWs were advised to take HCQ as prophylaxis after getting an electrocardiogram (ECG) while being posted to look after COVID-19 patients. A follow-up ECG was repeated for those who took HCQ. The normal upper limit for QTc interval of 460 milliseconds (ms) for females and 450 ms for males was considered.
A baseline ECG was analyzed for 250 HCWs with a median age of 35 (30-43) years. The median QTc was 410 (395-421) ms with the prevalence of prolonged QTc of 1.8% in females and 0% in males. A follow-up ECG after HCQ intake for 43 HCWs was further analyzed. They had a median age of 35 (31-39) years and took an average dose of HCQ of 2372 ± 839 mg. Pre- and post-HCQ chemoprophylaxis QTc interval (ms) was as follows: 408 (386-419) and 405 (387-417), with = 0.434, respectively.
Among Indian HCWs, the prevalence of prolonged QTc is 1.8% and 0% in females and males, respectively. HCQ intake as chemoprophylaxis for COVID-19 did not affect their QTc interval.
本研究旨在评估在管理2019冠状病毒病（COVID-19）病例时服用羟氯喹（HCQ）进行预防的印度医护人员中QTc间期延长的发生率及是否有变化。
在COVID-19大流行开始时，根据印度医学研究理事会（ICMR）的政策，建议医护人员在被安排照顾COVID-19患者时，在进行心电图（ECG）检查后服用HCQ进行预防。对服用HCQ的人员重复进行随访心电图检查。QTc间期的正常上限女性为460毫秒（ms），男性为450 ms。
对250名医护人员的基线心电图进行了分析，他们的中位年龄为35（30 - 43）岁。QTc中位数为410（395 - 421）ms，女性QTc延长的患病率为1.8%，男性为0%。对43名服用HCQ后的医护人员的随访心电图进行了进一步分析。他们的中位年龄为35（31 - 39）岁，平均服用HCQ剂量为2372 ± 839 mg。HCQ化学预防前后的QTc间期（ms）如下：408（386 - 419）和405（387 - 417），P = 0.434。
在印度医护人员中，女性和男性QTc延长的患病率分别为1.8%和0%。服用HCQ作为COVID-19的化学预防措施并未影响他们的QTc间期。
